Author

Laurent Peyrin-Biroulet

COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE

Laurent Peyrin-Biroulet  et al.

DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH

Laurent Peyrin-Biroulet  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

Laurent Peyrin-Biroulet  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Laurent Peyrin-Biroulet  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Laurent Peyrin-Biroulet  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

Laurent Peyrin-Biroulet  et al.

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Laurent Peyrin-Biroulet  et al.

PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

Laurent Peyrin-Biroulet  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Laurent Peyrin-Biroulet  et al.

Item 81 - 89 / 89
1 2 3 4
5